Journal of Ovarian Research - Pegylated liposomal doxorubicin in ovarian cancer treatment: A mono-institutional retrospective analysis. Do we still need it?

Journal of Ovarian Research | Abstract | Pegylated liposomal doxorubicin in ovarian cancer treatment: A mono-institutional retrospective analysis. Do we still need it?

 Conclusions

No evidence of superiority if PLD was compared to alternative agents was found in this analysis, particularly in the platinum-refractory setting. Our findings indicate a modest therapeutic activity of PLD in OC. Analysis of cost/benefit of PLD in OC is eagerly awaited.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.